Quarterly report pursuant to Section 13 or 15(d)

Segment Information

Segment Information
6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Segment Information Segment Information
ASC 280, Segment reporting, establishes annual and interim reporting standards for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenue and incur expenses, and for which discrete financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources and assess performance.

We are a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our operating segments are identified in the same manner as they are reported internally and used by our chief operating decision maker for the purpose of evaluating performance and allocating resources. Historically, we have disclosed one reportable segment. On March 23, 2022, we entered into the Merger Agreement, pursuant to which APAC will combine with OmniAb, and acquire the OmniAb Business, in a Reverse Morris Trust transaction. Immediately prior to the Merger and pursuant to the Separation Agreement, we will, among other things, transfer the OmniAb Business, including but not limited to the equity interests of Ab Initio Biotherapeutics, Inc., Crystal Bioscience, Inc., Icagen, LLC, Taurus Biosciences, LLC and xCella Biosciences, Inc. to OmniAb (the “Reorganization”) and, in connection therewith, will distribute (the “Distribution”) to Ligand stockholders 100% of the common stock of OmniAb. Immediately following the Distribution, Merger Sub will merge with and into OmniAb (the “Merger”), with OmniAb continuing as the surviving company in the Merger and as a wholly owned subsidiary of APAC.

In connection with the execution of the Merger Agreement, we have made organizational changes to better align our organizational structure with our strategy and operations, and management has reorganized the reportable segments to better reflect how the business is evaluated by the chief operating decision maker. Beginning in the first quarter of 2022, we operate the following two reportable segments: (1) OmniAb business and (2) Ligand core business. The OmniAb business segment is focused on enabling the discovery of therapeutic candidates for our partners by pairing antibody repertoires generated from our proprietary transgenic animals with our OmniAb business platform screening tools. The Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines.

Our chief operating decision maker relies on internal management reporting processes that provide revenue and operating income by reportable segment for making financial decisions and allocating resources. Segment operating income (loss) represents income (loss) before income taxes, interest income, interest expense, other income (expense), net, unallocated share-based compensation, and unallocated corporate overhead. Our management does not evaluate, manage or measure performance of segments using asset information; accordingly, asset information by segment is not prepared or disclosed.

The following table provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes (in thousands):
Three Months Ended June 30, Six Months Ended June 30,
2022 2021 2022 2021
OmniAb business revenue
  Royalties $ 139  $ —  $ 402  $ — 
  Contract 7,153  5,821  16,068  14,380 
Total OmniAb business revenue
7,292  5,821  16,470  14,380 
Ligand core business revenue
  Royalties 17,820  8,616  31,252  $ 15,728 
  Captisol - Core 3,325  9,682  9,551  10,935 
  Captisol - COVID 26,220  52,827  32,116  82,846 
  Contract 2,762  7,729  13,723  15,936 
 Total Ligand core business revenue 50,127  78,854  86,642  125,445 
     Total revenue $ 57,419  $ 84,675  $ 103,112  $ 139,825 
Segment operating income (loss)
OmniAb business
$ (8,998) $ (7,806) $ (15,187) $ (12,410)
Ligand core business 17,039  61,834  27,030  80,280 
Total segment operating income 8,041  54,028  11,843  67,870 
Unallocated corporate items
Shared-based compensation 5,136  5,748  10,793  10,618 
Other corporate expenses 3,374  2,541  10,825  6,798 
  Total unallocated corporate items 8,510  8,289  21,618  17,416 
Income (loss) from operations $ (469) $ 45,739  $ (9,775) $ 50,454